Skip to main content
. Author manuscript; available in PMC: 2014 Mar 19.
Published in final edited form as: Eur J Dermatol. 2013 Sep-Oct;23(5):618–628. doi: 10.1684/ejd.2013.2155

Figure 2. In vivo pharmacodynamics and pharmacokinetics of formulated TMX-202, IMQ or Aldara.

Figure 2

(A) Wild type mice were treated with a gel formulation of TMX-202, IMQ, or Aldara using 1 cm2-window stencils. The sera were collected 0, 1, 2, 4, 6, 24, 48, and 72 hrs after application. The levels of TNFα, KC, or IL-6 and were measured by Luminex assay. * and ** denote p<0.05 and p<0.001, respectively, by two-way ANOVA with Bonferroni post hoc testing. (B) The concentrations of TMX-202 and IMQ in the serum (1, 2, 4, and 6 hrs) were determined by Nikem. * denotes p<0.05 by two-way ANOVA with Bonferroni post hoc testing.